Terns Pharmaceuticals, Inc. (TERN) Stock Analysis

Not Halal Healthcare
Price $52.95
Market Cap $4.76B

Is TERN a good investment?

Terns Pharmaceuticals, Inc. (TERN) has a Plutrex AI rating of pending review as of May 26, 2026, indicating a pending review consensus. The stock is not classified as halal-compliant.

Related Halal Stocks

Related Stocks

Frequently Asked Questions

Is TERN a halal stock?

No, Terns Pharmaceuticals, Inc. (TERN) is currently not classified as halal by AAOIFI criteria.

What is Plutrex's AI rating for TERN?

Terns Pharmaceuticals, Inc. (TERN) has a Plutrex AI rating of pending review with a pending review consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.

Is TERN a good investment?

According to Plutrex AI, TERN has a pending review rating (pending review). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.

How can I invest in TERN?

US stocks like TERN can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. Plutrex provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.

What are the main risks of investing in TERN?

Plutrex AI identifies the main risks for TERN by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.

Chat with Plutrex AI about TERN

Ask anything about this stock and get an instant AI-powered answer — free, no signup required.

Open TERN in Plutrex